Sight Sciences, Inc.
Close on Oct 19, 2026
- Market cap
- $450.22M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $23.40M | $-0.08 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | After market close | $19.70M | $-0.24 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 4, 2026 | After market close | $20.40M | $-0.08 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $19.90M | $-0.16 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | $19.60M | $-0.23 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $17.50M | $-0.28 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 5, 2025 | After market close | $19.10M | $-0.23 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | $20.20M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | After market close | $21.40M | $-0.25 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 7, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 7, 2023 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| adjusted operating expensesnon-GAAP | full year 2026 | $92.00M to $94.00M | Lowered |
| increase compared to 2025non-GAAP | full year 2026 | 5% to 7% growth | Lowered |
| year-over-year growth | full year 2026 | 14% to 19% growth | Raised |
| growth | full year 2026 | 4% to 7% growth | Lowered |
| revenue guidance | full year 2026 | $88.00M to $92.00M | Raised |
| Interventional Glaucoma revenue | full year 2026 | $79.00M to $81.00M | Lowered |
| Interventional Dry Eye revenue | full year 2026 | $9.00M to $11.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Sight Sciences filed with the SEC
Sight Sciences Reports Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
[[ Our Mission Develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care — empowering people to keep seeing. | 3
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Sight Sciences Reports First Quarter 2026 Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
[[ Our Mission Develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care — empowering people to keep seeing. | 3
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent
Regulation FD disclosure · EX-99.1 to Form 8-K
Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
[[ Our Mission Develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care — empowering people to keep seeing. | 3
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Sight Sciences Reports Third Quarter 2025 Financial Results and
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Sight Sciences Investor Presentation November 2025
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Creating a New Category for Reimbursed Interventional Dry Eye Treatment Investor Presentation October 2025
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Sight Sciences Reports Second Quarter 2025 Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Sight Sciences Investor Presentation August 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Sight Sciences Reports First Quarter 2025 Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Sight Sciences Investor Presentation May 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Sight Sciences Appoints Gary Burbach to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Sight Sciences MISSION STATEMENT Develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights
Results of operations · EX-99.1 to Form 8-K
Sight Sciences Reports Third Quarter 2024 Financial Results and
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Sight Sciences MISSION STATEMENT Develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing.
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
Sight Sciences Reports Second Quarter 2024 Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Sight Sciences MISSION STATEMENT Develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Sight Sciences Reports First Quarter 2024 Financial Results and
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Acquisition or disposition completed · Regulation FD disclosure · EX-99.2 to Form 8-K
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict
Other events · EX-99.1 to Form 8-K
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Our Mission Develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing. Eyecare Innovation in Glaucoma and Dry Eye
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules
Material agreement · Agreement terminated · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Sight Sciences Reports Third Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Our Mission Transform treatment of Eye Diseases by treating underlying causes Earlier intervention helps restore the natural functionality of healthy eyes thereby improving long-term outcomes Eyecare Innovation in Glaucoma and Dry Eye
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Sight Sciences Appoints Matt Link as Chief Commercial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Sight Sciences Provides Revenue Guidance For the Third Quarter of 2023 and
Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Sight Sciences Reports Second Quarter 2023 Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Delivering the Power of Sight Investor Presentation August 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Delivering the Power of Sight Investor Presentation May 2023 ®
Regulation FD disclosure · EX-99 to Form 8-K
Sight Sciences Reports First Quarter 2023 Financial Results and
Results of operations · EX-99 to Form 8-K